Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 145.89% | -92.43% | -88.33% | -- | -40.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 145.89% | -92.43% | -88.33% | -- | -40.17% |
| Cost of Revenue | -- | -- | -286.15% | -- | -- |
| Gross Profit | 129.71% | -87.61% | -45.59% | -- | -40.17% |
| SG&A Expenses | 257.72% | 128.94% | -20.70% | 65.62% | -21.91% |
| Depreciation & Amortization | 73.50% | 85.34% | 68.69% | 19.59% | 19.39% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 237.68% | -10.22% | -49.76% | 66.85% | 89.40% |
| Operating Income | -263.13% | -290.23% | -351.90% | -23.70% | -372.24% |
| Income Before Tax | -241.88% | -1,404.49% | -171.64% | -21.47% | -209.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -241.88% | -1,404.49% | -171.64% | -21.47% | -209.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -241.88% | -1,404.49% | -171.64% | -21.47% | -209.14% |
| EBIT | -263.13% | -290.23% | -351.90% | -23.70% | -372.24% |
| EBITDA | -287.25% | -271.86% | -345.05% | -28.82% | -530.14% |
| EPS Basic | -194.74% | -1,400.00% | -157.14% | -13.33% | -216.67% |
| Normalized Basic EPS | -191.67% | -1,250.00% | -175.00% | -10.53% | -200.00% |
| EPS Diluted | -194.74% | -1,400.00% | -157.14% | -13.33% | -216.67% |
| Normalized Diluted EPS | -191.67% | -1,250.00% | -175.00% | -10.53% | -200.00% |
| Average Basic Shares Outstanding | 17.09% | 2.42% | 2.97% | 7.41% | 4.71% |
| Average Diluted Shares Outstanding | 17.09% | 0.18% | 2.97% | 7.41% | 4.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |